These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7910120)

  • 1. An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy.
    Kroemer HK; Fromm MF; Bühl K; Terefe H; Blaschke G; Eichelbaum M
    Circulation; 1994 May; 89(5):2396-400. PubMed ID: 7910120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereoselective steady state disposition and action of propafenone in Chinese subjects.
    Li G; Gong PL; Qiu J; Zeng FD; Klotz U
    Br J Clin Pharmacol; 1998 Nov; 46(5):441-5. PubMed ID: 9833596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mirror, mirror on the wall ... stereochemistry in therapeutics.
    Roden DM
    Circulation; 1994 May; 89(5):2451-3. PubMed ID: 7910122
    [No Abstract]   [Full Text] [Related]  

  • 4. Different stereoselective effects of (R)- and (S)-propafenone: clinical pharmacologic, electrophysiologic, and radioligand binding studies.
    Stoschitzky K; Klein W; Stark G; Stark U; Zernig G; Graziadei I; Lindner W
    Clin Pharmacol Ther; 1990 Jun; 47(6):740-6. PubMed ID: 2162749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective disposition and pharmacologic activity of propafenone enantiomers.
    Kroemer HK; Funck-Brentano C; Silberstein DJ; Wood AJ; Eichelbaum M; Woosley RL; Roden DM
    Circulation; 1989 May; 79(5):1068-76. PubMed ID: 2713973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of the stereoisomers of propafenone and diprafenone in guinea-pig heart.
    Groschner K; Lindner W; Schnedl H; Kukovetz WR
    Br J Pharmacol; 1991 Mar; 102(3):669-74. PubMed ID: 1364837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism.
    Kroemer HK; Fischer C; Meese CO; Eichelbaum M
    Mol Pharmacol; 1991 Jul; 40(1):135-42. PubMed ID: 1857335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of propafenone.
    Hii JT; Duff HJ; Burgess ED
    Clin Pharmacokinet; 1991 Jul; 21(1):1-10. PubMed ID: 1914339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone.
    Lee JT; Kroemer HK; Silberstein DJ; Funck-Brentano C; Lineberry MD; Wood AJ; Roden DM; Woosley RL
    N Engl J Med; 1990 Jun; 322(25):1764-8. PubMed ID: 1971708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man.
    Brode E; Müller-Peltzer H; Hollmann M
    Methods Find Exp Clin Pharmacol; 1988 Nov; 10(11):717-27. PubMed ID: 3221745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects.
    Mörike KE; Roden DM
    Clin Pharmacol Ther; 1994 Jan; 55(1):28-34. PubMed ID: 7905369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselective metabolism of propafenone by human liver CYP3A4 expressed in transgenic Chinese hamster CHL cells lines.
    Zhou Q; Yao TW; Yu YN; Zeng S
    Acta Pharmacol Sin; 2001 Oct; 22(10):944-8. PubMed ID: 11749780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Specific and nonspecific effects of beta receptor blockers: stereoselectively different properties exemplified by (R)- and (S)-propranolol].
    Stoschitzky K; Lindner W
    Wien Med Wochenschr; 1990 Apr; 140(6-7):156-62. PubMed ID: 1971978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propafenone shows class Ic and class II antiarrhythmic effects.
    Stoschitzky K; Stoschitzky G; Lercher P; Brussee H; Lamprecht G; Lindner W
    Europace; 2016 Apr; 18(4):568-71. PubMed ID: 26056191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-blocking effect of propafenone based on spectral analysis of heart rate variability.
    Lombardi F; Torzillo D; Sandrone G; Dalla Vecchia L; Finocchiaro ML; Bernasconi R; Cappiello E
    Am J Cardiol; 1992 Oct; 70(11):1028-34. PubMed ID: 1357951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology and beta-blocking efficacy of propafenone.
    Barbey JT
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S41-3. PubMed ID: 1723117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concentration dependent stereoselectivity of propafenone N-depropylation metabolism with human hepatic recombinant CYP1A2.
    Zhou Q; Yao TW; Yu YN; Zeng S
    Pharmazie; 2003 Sep; 58(9):651-3. PubMed ID: 14531463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The differentiation of propafenone from other class Ic agents, focusing on the effect on ventricular response rate attributable to its beta-blocking action.
    Faber TS; Camm AJ
    Eur J Clin Pharmacol; 1996; 51(3-4):199-208. PubMed ID: 9010685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of R- and S-propafenone and of the main metabolite in plasma.
    Böhm R; Ellrich R; Koytchev R
    Pharmazie; 1995 Aug; 50(8):542-5. PubMed ID: 7568317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of clinically significant beta-blocking effect of propafenone.
    Cheriex EC; Krijne R; Brugada P; Heymeriks J; Wellens HJ
    Eur Heart J; 1987 Jan; 8(1):53-6. PubMed ID: 2880719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.